)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Jubilant Pharmova Limited (530019) investor relations material
Jubilant Pharmova Limited Q1 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 25/26 earnings summary1 Aug, 2025
Executive summary
Achieved 10% year-over-year revenue growth in Q1'FY26, with EBITDA and PAT margin expansion across all business units.
Vision 2030 targets doubling revenues, 23–25% EBITDA margin, zero net debt, and high teens ROCE by FY30.
Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with results reviewed by the Audit Committee and limited review by statutory auditors.
API business classified as discontinued operations following approval of its sale to a wholly-owned subsidiary; continuing operations now comprise management and support services.
Major growth drivers include expansion in radiopharma, allergy immunotherapy, CDMO sterile injectables, CRDMO, and generics.
Financial highlights
Q1'FY26 revenue: Rs. 1,901 Cr, up 10% year-over-year; EBITDA: Rs. 302 Cr, up 14% year-over-year; EBITDA margin: 15.8%.
Consolidated revenue from operations was ₹18,789 million, up from ₹17,204 million year-over-year.
Normalized PAT: Rs. 103 Cr, up 48% year-over-year; Normalized PAT margin: 5.4%.
Consolidated net profit for the quarter was ₹1,025 million, compared to ₹4,818 million in the same quarter last year.
All business segments reported year-over-year revenue growth, with notable EBITDA margin improvements in generics and CRDMO.
Outlook and guidance
On track to double revenues by FY30, with EBITDA margin guidance of 23–25% and zero net debt.
API business sale expected to complete by September 1, 2025, with no impact on consolidated results as the transaction is with a wholly-owned subsidiary.
Radiopharma and CDMO sterile injectables to drive margin expansion through new product launches and capacity doubling.
Generics and API businesses targeting top quartile profitability and margin improvement.
Proprietary novel drugs to explore monetization via licensing or external funding, with clinical data readouts expected in CY2026.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Jubilant Pharmova Limited earnings date
Q2 202631 Oct, 2025
Next Jubilant Pharmova Limited earnings date
Q2 202631 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Jubilant Pharmova Limited is a pharmaceutical company engaged in the development, manufacturing, and supply of specialty pharmaceuticals and contract research services. The company operates across segments including contract development and manufacturing (CDMO), radiopharma, allergy therapy products, and proprietary pharmaceuticals. It also provides drug discovery and development services to global pharmaceutical and biotechnology companies. The company is headquartered in Noida, India, and its shares are listed on the BSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage